Filing Flows › Xeris Biopharma Holdings (XERS) › Q3 2025
Xeris Biopharma Holdings (XERS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Xeris Biopharma Holdings (XERS) reported revenue of $74.4M for the third quarter 2025 (Q3 2025), +37% from a year earlier and +4% from the quarter before. Operating margin was 9.0%, net earnings $621K (0.8% of revenue).
Xeris Biopharma Holdings, Q3 2025: revenue $74.4M (+37% year over year), operating margin 9.0%, net earnings $621K, operating cash flow $18.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $74.4M | +4% | +37% |
| Operating profit | $6.7M | +50% | — |
| Net earnings | $621K | — | — |
| Operating cash flow | $18.4M | 101× | — |
What changed
Revenue was $74.4M in Q3 2025, up 37% year over year and up 4% from the previous quarter. Recorlev was the largest line at 50% of revenue. Recorlev added $19.2M year over year (up 109%), 96% of the total change. Royalty, contract and other revenue declined 77%.
Operating profit was $6.7M, a 9.0% margin (up 32.8 points year over year). Total costs grew 1% against revenue growth of 37%. The fastest-growing cost line was Research & development (+27%). Net earnings were $621K. The effective tax rate was 0.0%.
Operating cash flow was $18.4M, 2968% of net earnings. Non-cash charges added back $338K of depreciation and amortization and $7.6M of share-based compensation. Working capital and other items added $9.8M.
Questions
What was Xeris Biopharma Holdings' revenue in the third quarter 2025?
Xeris Biopharma Holdings (XERS) reported revenue of $74.4M for the third quarter 2025 (Q3 2025), +37% from a year earlier and +4% from the quarter before.
Was Xeris Biopharma Holdings profitable in the third quarter 2025?
Operating profit was $6.7M (9.0% of revenue) and net earnings $621K.